• Recruiting

NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma


NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma


ORIC533

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma


The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options


Sponsor

ORIC Pharmaceuticals


Locations

United States, California

United States, Minnesota

 

ClinicalTrials.gov Identifier: NCT05227144


Official Title: An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma


First Posted : February 7, 2022


Click here for details on ClinicalTrials.Gov

 

Drug: ORIC-533

 

ORIC 533


CD73 Inhibitor ORIC-533 (Code C185560)

CD73 Inhibitor ORIC-533

ORIC 533

ORIC-533

ORIC533

 

Location

United States, California

United States, Minnesota

Posts Archive